Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
ConclusionAlthough the triweekly six-course regimen of TCbH achieved a high pCR rate, hematological AEs frequently occurred during the latter part of the chemotherapy course. One-third of patients experienced delayed or discontinued chemotherapy.Clinical registration number:http://www.umin.org.auUMIN000013513.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Anorexia | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Eating Disorders & Weight Management | Hematology | HER2 | Herceptin | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study | Taxotere | Thrombocytopenia | Toxicology | Women